Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Khalid Aziz

Gastroenterology Framingham, MA Medical Doctor

NPI 1538165055 CMS profile 24294

43 Lincoln St, Framingham, MA 01702

Open in the dashboard

General payments

$10,392

537 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Khalid Aziz of Framingham, MA is reported in the CMS Open Payments database as having received $10,392 across 537 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,084 50
2024 General $1,371 56
2023 General $1,250 63
2022 General $1,343 76
2021 General $1,915 123
2020 General $1,343 76
2019 General $2,087 93

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Khalid Aziz
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Khalid Aziz were reported at $1,084. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Khalid Aziz Gastroenterology median Middle half National median
2019 $2,087 $417 $126–$1,100 $163
2020 $1,343 $224 $74–$624 $114
2021 $1,915 $352 $106–$1,054 $132
2022 $1,343 $448 $129–$1,270 $149
2023 $1,250 $533 $150–$1,390 $160
2024 $1,371 $605 $160–$1,606 $164
2025 $1,084 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,949 126 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,177 88 payments
  3. Nestle HealthCare Nutrition Inc. $1,069 54 payments
  4. Phathom Pharmaceuticals, Inc. $999 48 payments
  5. QOL Medical, LLC $857 31 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $645 42 payments
  7. RedHill Biopharma Inc. $402 29 payments
  8. Gilead Sciences, Inc. $379 5 payments
  9. Pfizer Inc. $331 18 payments
  10. Concordia Pharmaceuticals Inc. $252 8 payments
  11. Other $2,334 88 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,361 534 payments
  2. Education $31 3 payments
Products named General payments · program years 2019–2025
  1. ZENPEP $1,166 59 payments
  2. LINZESS $1,064 93 payments
  3. CREON $978 67 payments
  4. XIFAXAN $978 74 payments
  5. Sucraid $636 22 payments
  6. VOQUEZNA Gastroenterology $566 26 payments
  7. VOQUEZNA Gastroenterology $433 22 payments
  8. TRULANCE $395 34 payments
  9. Talicia $380 28 payments
  10. XELJANZ $331 18 payments
  11. Other $5,352 263 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

3,039

Median for Gastroenterology: 569

Drug cost

$1,159,576

Median for Gastroenterology: $104,976

Branded share of claims

39%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sucraid Sacrosidase Brand 29 $395,503
Ibsrela Tenapanor Hcl Brand 82 $166,209
Xifaxan Rifaximin Brand 31 $138,281
Linzess Linaclotide Brand 217 $125,979
Xeljanz Tofacitinib Citrate Brand 12 $68,296
Rezdiffra Resmetirom Brand 14 $54,646
Voquezna Vonoprazan Fumarate Brand 80 $50,739
Zenpep Lipase/Protease/Amylase Brand 23 $44,709
Creon Lipase/Protease/Amylase Brand 18 $35,800
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 227 $14,461

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$183,896

Medicare's payments for the services billed

Medicare patients

699

Average age 71

Services billed

1,705

364 women, 335 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 45%
Depression 33%
Diabetes 28%
Ischemic heart disease 27%
Chronic kidney disease 27%
COPD 23%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $453
$453 80 —
Bylvay
  • Ipsen Biopharmaceuticals, Inc $152
$152 — —
CREON
  • AbbVie, Inc. $143
$143 18 —
Sucraid
  • QOL Medical, LLC $122
$122 29 —
DUPIXENT
  • GENZYME CORPORATION $122
$122 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

537 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record